Its activation mitigates clinical symptoms, and Drd2 knockout (Drd2KO) mice develop severe symptoms of RA; D2R antagonists induce the accumulation of IL-17+ and IL-6+ T cells in synovial fluid, exacerbating the inflammatory process. Here, DRD2 is linked to rheumatoid arthritis.